2-(6-溴吡啶-3-基)乙胺 | 910391-38-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-(6-溴吡啶-3-基)乙胺
• 英文名称: 2-(6-Bromopyridin-3-yl)ethanamine
• CAS: 910391-38-7
• 化学式: C₇H₉BrN₂
• 分子量: 201.06
• InChiKey: FYYOUQWQNLWSBC-UHFFFAOYSA-N

物化性质

• 沸点：
  299.8±25.0 °C(Predicted)
• 密度：
  1.485±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES<br/>[FR] INHIBITEURS DE KINASES ASSOCIÉES AUX RÉCEPTEURS D'INTERLEUKINE À BASE D'AMIDOPYRAZOLE
  申请人：MERCK SHARP & DOHME

  公开号：WO2012129258A1

  公开（公告）日：2012-09-27

  This invention relates to amidopyrazole compounds that are inhibitors of Interleukin receptor-associated kinases, in particular IRAK-4, and are useful in the treatment of cellular proliferative diseases, for example, cancer, hyperplasia, restenosis, cardiac hypertrophy, immune disorders and inflammation.

  这项发明涉及抗干扰素受体相关激酶（特别是IRAK-4）的抑制剂——amidopyrazole化合物，可用于治疗细胞增殖性疾病，例如癌症、增生、再狭窄、心肌肥大、免疫紊乱和炎症。
• [EN] 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS<br/>[FR] 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES SUBSTITUES EN POSITION 6 EN TANT QU'AGONISTES DE RECEPTEUR 5-HT2C
  申请人：LILLY CO ELI

  公开号：WO2005082859A1

  公开（公告）日：2005-09-09

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: I where: R6 is -C=C-R10, -O-R12, -S-R14, or -NR24R25; and other substituents are as defined in the specification.

  本发明提供了公式I中的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环庚烯作为选择性5-HT2C受体激动剂，用于治疗与5-HT2C相关的疾病，包括肥胖症、强迫症/强迫性障碍、抑郁症和焦虑症：I其中：R6为-C=C-R10，-O-R12，-S-R14或-NR24R25；其他取代基如规范中所定义。
• [EN] SUBSTITUTED THIENYL-MERCAPTOKETONES, AND USE THEREOF FOR TREATING DISEASES ASSOCIATED WITH HISTONE DEACETYLASE ENZYMATIC ACTIVITY<br/>[FR] THIENYL-MERCAPTOKETONES SUBSTITUES, ET UTILISATION ASSOCIEE POUR LE TRAITEMENT DE MALADIES LIEES A L'ACTIVITE ENZYMATIQUE D'HISTONE DEACETYLASE
  申请人：ARGENTA DISCOVERY LTD

  公开号：WO2005075466A1

  公开（公告）日：2005-08-18

  A compound of formula: (I): in which A represents optionally substituted monocyclic heteroaryl or phenyl; B represents optionally substituted heteroaryl, aryl, aryl-fused-heterocycloalkyl, heteroaryl-fused-cycloalkyl, heteroaryl-fused-heterocycloalkyl or aryl-fused-cycloalkyl, or B represents H when L represents a single bond; L represents a single bond, alkylene, (CH2)nX(CH2)m, (CH2)nX(CH2)pY(CH2)m; X represents -O-, -NR3-, -CO-, -SO2-, -NR3CO-, -NR3SO2-, -CONR3-, -SO2NR3-, -NR5CONR5a-; Y represents NR3- or -O-; R1 represents H, COR8; R2 represents halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, CN; R3 represents H, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkylalkyl, or alkyl substituted by -OR4, -NR5R6, -NR6COR7, -NR6SO2R7, -CONR5R6 or -SO2NR5R6; R4 represents H, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl or cycloalkyl; R5 and R5a represent H or alkyl; R6 represents H, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl or cycloalkyl or NR5R6 represents a cyclic amine; R7 represents alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl; R8 represents alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl; n represents 0-3; m represents 0-3; p represents 1-3; and corresponding disulphides, N-oxides, pharmaceutically acceptable salts, solvates and prodrugs thereof; and use to treat a disease in which inhibition of histone deacetylase can prevent, inhibit or ameliorate the pathology and/or symptomatology of the disease.

  化合物的公式为（I）：其中A代表可选取代的单环杂芳基或苯基；B代表可选取代的杂芳基、芳基、芳基融合杂环烷基、杂芳基融合环烷基、杂芳基融合杂环烷基或芳基融合环烷基，或当L代表单键时，B代表H；L代表单键、烷基、（CH2）nX（CH2）m、（CH2）nX（CH2）pY（CH2）m；X代表-O-、-NR3-、-CO-、-SO2-、-NR3CO-、-NR3SO2-、-CONR3-、-SO2NR3-、-NR5CONR5a-；Y代表NR3-或-O-；R1代表H、COR8；R2代表卤素、烷基、卤代烷基、烷氧基、卤代烷氧基、CN；R3代表H、烷基、芳基烷基、杂芳基烷基、杂环烷基烷基、环烷基烷基或烷基取代的-OR4、-NR5R6、-NR6COR7、-NR6SO2R7、-CONR5R6或-SO2NR5R6；R4代表H、烷基、芳基烷基、杂芳基烷基、杂环烷基烷基、环烷基烷基、芳基、杂芳基、杂环烷基或环烷基；R5和R5a代表H或烷基；R6代表H、烷基、芳基烷基、杂芳基烷基、杂环烷基烷基、环烷基烷基、芳基、杂芳基、杂环烷基或环烷基，或NR5R6代表环状胺基；R7代表烷基、芳基、杂芳基、环烷基、杂环烷基、芳基烷基、杂芳基烷基、环烷基烷基或杂环烷基烷基；R8代表烷基、芳基、杂芳基、环烷基、杂环烷基、芳基烷基、杂芳基烷基、环烷基烷基或杂环烷基烷基；n代表0-3；m代表0-3；p代表1-3；以及相应的二硫化物、N-氧化物、药学上可接受的盐、溶剂化合物和前药；并用于治疗一种疾病，其中组蛋白去乙酰化酶的抑制可以预防、抑制或改善该疾病的病理学和/或症状学。
• 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1720836A1

  公开（公告）日：2006-11-15
• LARGE SUBSTITUENT, NON-PHENOLIC AMINE OPIOIDS
  申请人：Rensselaer Polytechnic Institute

  公开号：EP2318372B1

  公开（公告）日：2015-01-14